Gastroenterology

Study Drug: Biological therapy involving already registered drugs from the IL-23 antagonist and IL-1 antagonist groups, which will be administered alone (monotherapy) or in combination with an experimental drug from the anti-a4B7 mAb group.

Study Drug: Experimental biological therapy that blocks the proinflammatory pathway of integrin α4β. Drugs targeting the same mechanism are already registered, but the experimental drug is taken in tablet form, unlike others that are administered by infusion.

Study Drug: Patients will receive either standard biological therapy (adalimumab) or experimental biological therapy with an IL-1 proinflammatory molecule blocker.

Study Drug: Experimental biological therapy that blocks the effect of the pro-inflammatory molecule TL1A.